文献速递间质性肺疾病肺结节与肺癌

免疫检查点抑制剂相关间质性肺病在癌症患者中的特征

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
PubMed 文献 · Eur Respir J · 2017-08-10

该回顾性研究分析了1826例使用免疫检查点抑制剂(ICI)的癌症患者,发现64例(3.5%)发生ICI相关间质性肺病(ICI-ILD)。中位发生时间为2.3个月,磨玻璃影最常见,6个月总生存率58.1%。

要点

  • ICI-ILD发生率为3.5%,中位发生时间2.3个月。
  • 磨玻璃影(81.3%)为主要影像学表现。
  • 肺癌患者ICI-ILD发生早于黑色素瘤患者。

核心结论

  • ICI-ILD常早期发生并具有提示性影像学特征,目前无明确危险因素,肿瘤科医生需诊断并适当治疗此不良事件。

主要发现

  • ICI-ILD患者主要为男性、既往或当前吸烟者,中位年龄59岁。
  • 65.6%为2/3级严重程度,9.4%为4级,9.4%为致死性ILD。
  • 从免疫治疗开始至ILD的中位时间(范围)为2.3(0.2-27.4)个月。
  • 肺癌患者ILD发生中位时间2.1个月,黑色素瘤患者5.2个月(p=0.02)。
  • 磨玻璃影(81.3%)为主要病变,其次为实变(53.1%);机化性肺炎(23.4%)和过敏性肺炎(15.6%)为最常见模式。

临床怎么用

  • 肿瘤科医生应警惕ICI-ILD的早期发生,依据影像学特征及时诊断并适当治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event.Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI-ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies.We identified 64 (3.5%) out of 1826 cancer patients with ICI-ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2-27.4) months. Onset tended to occur earlier in lung cancer versus melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7-73.8%).ICI-ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017. PMID: 28798088. doi:10.1183/13993003.00050-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。